GeneDx Holdings Corp. (WGS) Guidance & Earnings Results

On 2026-08-03 GeneDx Holdings Corp. reaffirmed guidance: "FY2026 revenue $475-$490M; exome/genome volume growth at least 30%; adjusted gross margin…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

WGSGeneDx Holdings Corp.Follow WGS — free

Diagnostics & Research · Healthcare

—

Price chart with a free account

Market cap: 1.7B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 26 Oct, in 2 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
3 Aug 26	Reaffirmed	FY2026 revenue $475-$490M; exome/genome volume growth at least 30%; adjusted gross margin ~70% · full year
4 May 26	Lowered	Full-year 2026 revenue guidance reduced from $540-555M to $475-490M; Q2 revenue guidance $110-112M · full year
23 Feb 26	Raised	2026 revenue guidance $540-555M, exome/genome revenue growth 33-35%, adjusted gross margin at least 70% · full year
12 Jan 26	Raised	FY2026 revenue guidance $540-$555M (28% YoY growth), exome/genome growth 33-35%, adjusted gross margin at least 70%, adjusted net income positive
28 Oct 25	Raised	Revenue guidance raised to $425-428M from $400-415M · full year
29 Jul 25	Raised	FY2025 revenue raised to $400-415M from $360-375M; exome/genome revenue growth raised to 48-52% from 30%; adjusted gross margin raised to 68-71% from 66-68%; adjusted net income positive each quarter and full year (unchanged) · full year

GeneDx Holdings Corp. — questions

What guidance did GeneDx Holdings Corp. give?: On 2026-08-03: "FY2026 revenue $475-$490M; exome/genome volume growth at least 30%; adjusted gross margin ~70%"
When does GeneDx Holdings Corp. report earnings?: GeneDx Holdings Corp.'s next earnings report is expected on 2026-10-26.

Every figure on this page comes from GeneDx Holdings Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.